Cardiac Ion Channelopathies Multi-Gene Panel, NGS
The ‘Cardiac Ion Channelopathies’ panel detects mutation in genes associated with cardiac channelopathies. These are a group of heritable ion channel disorders that are associated with cardiac arrhythmias and sudden cardiac death in the presence of a structurally normal heart. These disorders have been associated with mutations in genes that encode cardiac ion channel subunits or proteins that interact with, and regulate, ion channels. Cardiac channelopathies that effect the Na+-ion channel include Brugada syndrome (BrS), long QT syndrome (LQTS), short QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Certain mutations can give rise to different phenotypes with enhanced or reduced channel function and even combinations of phenotypes. Affected individuals have a structurally normal heart but an increased risk of syncope and sudden cardiac death (SCD) caused by ventricular tachycardia (VT) or ventricular fibrillation (VF).
Brugada syndrome Brugada syndrome is inherited as either an autosomal dominant or X-linked recessive disorder characterized by cardiac conduction abnormalities (ST-segment abnormalities in leads V1-V3 on ECG) and a high risk for ventricular arrhythmias that can result in sudden death. In 20–40% of the affected patients, mutations in the SCN5A gene have been identified which cause a loss of function in the sodium ion channel. The defective myocardial sodium channels reduce sodium inflow currents, thereby reducing the duration of normal action potentials. Other minor contributors to BrS are mutations in the genes SCN1B (sodium channel beta-1 subunit), SCN3B (beta-3 subunit of the cardiac sodium channel) and GPD1-L. The prevalence of BrS is estimated to be ∼35/100,000 person/year. Brugada syndrome presents primarily during adulthood although age at diagnosis may range from infancy to late adulthood. The mean age of sudden death is approximately 40 years. Clinical presentations may also include sudden infant death syndrome (SIDS; death of a child during the first year of life without an identifiable cause) and the sudden unexpected nocturnal death syndrome (SUNDS) seen in individuals from Southeast Asia. Other conduction defects can include first-degree AV block, intraventricular conduction delay, right bundle branch block, and sick sinus syndrome.
Long QT syndrome (LQTS) LQTS is a cardiac channelopathy characterized by a QT segment prolongation and can result in ventricular tachyarrhythmias with associated episodes of syncope and SCD. LQTS is one of the leading causes of SCD among young people. It can be congenital or acquired, the latter is generally associated with drugs and electrolyte imbalances (hypokalemia, hypocalcemia, and hypomagnesemia). The clinical presentation can be variable, ranging from asymptomatic to episodes of syncope and SD caused by ventricular tachyarrhythmias (torsade de pointes). Prolongation of the QT interval may arise because of a decrease in the K+ repolarization currents or to an inappropriate delay in the entry of Na+ into the myocyte. 10–15% of the LQTS cases are related to mutations in SCN5A (Type 3 LQTS). Individuals with Type 3 LQTS present arrhythmias associated with bradycardia and symptoms at rest, especially during sleep. Type 3 LQT patients do not respond as well to β-blockers, and the presence of a long QT3 mutation is a sign of high risk for cardiac events. LQTS Type 10 is caused by a mutation in the SCN4B gene, which encodes the β4-subunit of the cardiac Na+ channel (Nav4b). This mutation induces a positive change in the inactivation of Na+ channels, which increases Na+ current and delays the repolarization in a similar fashion to Type 3 LQTS. Genetic testing in LQTS can detect an underlying mutation in 60–70% of patients.
Short QT syndrome (SQTS) SQTS is a clinically malignant entity characterized by a short QT interval (<330 milliseconds), with tall, symmetric and peaked T waves leading to ventricular arrhythmias and the potential for SCD in the neonatal period. Most patients have a family history of SCD with an autosomal dominant pattern of transmission and high penetrance. Type 1 SQTS has been associated with the KCNH2 gene (human-ether-a-go-go-related gene), which induces a fast activation of K+ currents, and shortened ventricular action potentials. SQTS Type 2 has been linked to mutations in the KCNQ1 gene. while SQTS Type 3 is caused by a mutation in KCNJ2 gene which accelerates the Phase 3 of the cardiac action potential. This latter form of short QT has a characteristic ECG pattern, described as an abrupt and sharp termination of the T wave.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) CPVT is a familial arrhythmogenic disorder characterized by the presence of SCD sometimes associated with bidirectional polymorphic ventricular tachycardia. Individuals show a normal resting ECG although adrenergic stimulation (vigorous exercise, fear, epinephrine infusion) may induce syncope and/or SCD. Two genetic forms have been identified as responsible for CPVT. First, CPVT Type 1, an autosomal dominant form caused by mutations (>120 have been identified to date) in the RyR2 gene (1q42–q43), encoding the ryanodine receptor. Second, CPVT Type 2, an autosomal recessive form, caused by mutations in calsequestrin (CASQ2) located at 1p13–p21. These genes are key players in the storage and release of calcium from the sarcoplasmatic reticulum. Both genes are therefore implicated in the mediation of excitation-contraction coupling. In general, mutations lead to increased intracellular Ca2+, leading to late depolarizations that predisposes to arrhythmias.
Panel Components Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: AKAP9, ANK2, CASQ2, CAV3, CACNA1C, CAV3, CACNA2D1, GPD1L, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNQ1, RYR2, SCN4B, SNTA1, SCN3B, CACNB2, SCN1B, and SCN5A associated with Cardiac Ion Channelopathies.
- Aid in the diagnosis of Brugada syndrome, long QT syndrome, short QT syndrome and catecholaminergic polymorphic ventricular tachycardia
- Providing a genetic evaluation for patients with a personal or family history of unexplained sudden cardiac death
- For appropriate management and surveillance for disease features based on the gene involved
- Identification of a pathogenic variant may assist with prognosis, clinical management, familial screening, and genetic counseling
The sequencing and deletion/duplication results for all genes on this panel are negative
Whole blood (EDTA), buccal swab (alternative).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- J Am Coll Cardiol. 2009;54: 2065-74. [PMID: 19926015]
- Proc Natl Acad Sci U S A. 2008;105: 9355-60. [PMID: 18591664]
- Genet 2010;87(5):701-707. [PMID: 21055718]
- Engl J Med 2006 Aug 24;355(8):788-798. [PMID: 16928994]
- Nat Genet 2007 Dec;39(12):1488-1493. [PMID: 17994018]
- Heart Rhythm. 2008;5: 1434-40. [PMID: 18929331]
- J Clin Invest. 2002;110: 1201-9. [PMID: 12393856]
- Circ Arrhythm Electrophysiol. 2009;2: 185-94. [PMID: 19808464]
- Version 2. J Med Genet. 2004;41: e66. [PMID: 15121794]
- Circulation. 2007;116: 2260-8. [PMID: 17967977]
- Circulation. 2002;105: 707-13. [PMID: 11839626]
- Clin Genet. 2003;63: 273-82. [PMID: 12702160]